A randomized trial showed Factor XIa inhibitor (abelacimab) compared with the currently used Factor Xa blocking agents (rivoroxaban) for atrial fibrillation led to significantly less bleeding events, leading to early trial termination
nejm.org/doi/full/10....
nejm.org/doi/full/10....
January 22, 2025 at 10:11 PM
A randomized trial showed Factor XIa inhibitor (abelacimab) compared with the currently used Factor Xa blocking agents (rivoroxaban) for atrial fibrillation led to significantly less bleeding events, leading to early trial termination
nejm.org/doi/full/10....
nejm.org/doi/full/10....
Interesting results with abelacimab in patients with A Fib @NEJM👇
Can uncoupling hemostasis and thrombosis by blocking activation of FXI also help address unmet needs in cancer-associated thrombosis?
Can’t wait to see the results of the on-going ASTER and MAGNOLIA trials
www.nejm.org/doi/full/10....
Can uncoupling hemostasis and thrombosis by blocking activation of FXI also help address unmet needs in cancer-associated thrombosis?
Can’t wait to see the results of the on-going ASTER and MAGNOLIA trials
www.nejm.org/doi/full/10....
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation | NEJM
Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in pati...
www.nejm.org
January 22, 2025 at 10:59 PM
Interesting results with abelacimab in patients with A Fib @NEJM👇
Can uncoupling hemostasis and thrombosis by blocking activation of FXI also help address unmet needs in cancer-associated thrombosis?
Can’t wait to see the results of the on-going ASTER and MAGNOLIA trials
www.nejm.org/doi/full/10....
Can uncoupling hemostasis and thrombosis by blocking activation of FXI also help address unmet needs in cancer-associated thrombosis?
Can’t wait to see the results of the on-going ASTER and MAGNOLIA trials
www.nejm.org/doi/full/10....
In the AZALEA–TIMI 71 trial, researchers compared the safety of the monoclonal antibody abelacimab with that of the direct oral anticoagulant rivaroxaban in patients with atrial fibrillation. Full trial results and Plain Language Summary: nej.md/3PJcknN
#MedSky #CardioSky
#MedSky #CardioSky
January 28, 2025 at 8:50 PM
In the AZALEA–TIMI 71 trial, researchers compared the safety of the monoclonal antibody abelacimab with that of the direct oral anticoagulant rivaroxaban in patients with atrial fibrillation. Full trial results and Plain Language Summary: nej.md/3PJcknN
#MedSky #CardioSky
#MedSky #CardioSky
Abelacimab significantly reduced bleeding events in atrial fibrillation patients compared to rivaroxaban, prompting early trial termination.
by Ruff CT, Patel SM (...) Sabatine MS et 16 al. in N Engl J Med #MedSky
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2406674
by Ruff CT, Patel SM (...) Sabatine MS et 16 al. in N Engl J Med #MedSky
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2406674
February 1, 2025 at 4:30 PM
Abelacimab significantly reduced bleeding events in atrial fibrillation patients compared to rivaroxaban, prompting early trial termination.
by Ruff CT, Patel SM (...) Sabatine MS et 16 al. in N Engl J Med #MedSky
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2406674
by Ruff CT, Patel SM (...) Sabatine MS et 16 al. in N Engl J Med #MedSky
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2406674
RCT of FXI inhibitor Abelacimab vs Rivaroxaban in AF stopped early due to significantly less bleeding with Abelacimab. Not powered to look at thrombotic events but were 7 on Rivaroxaban and 10 and 11 on the two doses of the FXI inhibitor. Paper in this week's New England Journal of Medicine.
January 22, 2025 at 11:46 PM
RCT of FXI inhibitor Abelacimab vs Rivaroxaban in AF stopped early due to significantly less bleeding with Abelacimab. Not powered to look at thrombotic events but were 7 on Rivaroxaban and 10 and 11 on the two doses of the FXI inhibitor. Paper in this week's New England Journal of Medicine.
This is the editorial in this week's New England Journal of Medicine to accompany the paper on the use of the FXI inhibitor Abelacimab in atrial fibrillation.
January 22, 2025 at 11:52 PM
This is the editorial in this week's New England Journal of Medicine to accompany the paper on the use of the FXI inhibitor Abelacimab in atrial fibrillation.
Novartis agrees $3bn deal to buy heart drug biotech from Blackstone
https://www.ft.com/content/6d2458c4-9c0b-4548-a387-c229dba73e26
https://www.ft.com/content/6d2458c4-9c0b-4548-a387-c229dba73e26
Novartis agrees $3bn deal to buy heart drug biotech from Blackstone
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019
www.ft.com
February 11, 2025 at 11:09 AM
Novartis agrees $3bn deal to buy heart drug biotech from Blackstone
https://www.ft.com/content/6d2458c4-9c0b-4548-a387-c229dba73e26
https://www.ft.com/content/6d2458c4-9c0b-4548-a387-c229dba73e26
I’m not much of an expert on clotting cascades, but I’m very much in favour of preventing strokes in any way that we can.
A short report in the @bmj.com of a @nejm.org study using a monoclonal antibody to target factor XI in patients with atrial fibrillation.
It sounds promising.
#MedSky
A short report in the @bmj.com of a @nejm.org study using a monoclonal antibody to target factor XI in patients with atrial fibrillation.
It sounds promising.
#MedSky
February 22, 2025 at 11:06 AM
Study compares abelacimab (150mg or 90mg monthly) vs. rivaroxaban (20mg daily) in AF patients at moderate-high stroke risk. Key findings set to reshape AF care! #CardioInnovation PMID:39842011, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2406674 🧪
February 25, 2025 at 12:10 PM
Study compares abelacimab (150mg or 90mg monthly) vs. rivaroxaban (20mg daily) in AF patients at moderate-high stroke risk. Key findings set to reshape AF care! #CardioInnovation PMID:39842011, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2406674 🧪
In patients with atrial fibrillation and moderate-to-high risk of stroke, abelacimab, a monoclonal antibody that inhibits activation of factor XI, led to fewer bleeding events than rivaroxaban. Read the full AZALEA–TIMI 71 trial results: nej.md/3PJcknN
#MedSky #Cardiology
#MedSky #Cardiology
January 24, 2025 at 2:20 PM
In patients with atrial fibrillation and moderate-to-high risk of stroke, abelacimab, a monoclonal antibody that inhibits activation of factor XI, led to fewer bleeding events than rivaroxaban. Read the full AZALEA–TIMI 71 trial results: nej.md/3PJcknN
#MedSky #Cardiology
#MedSky #Cardiology
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.
www.nejm.org/doi/full/10....
@nejm.org
#CardioSky #MedSky #Cardiology #AtrialFibrillation
www.nejm.org/doi/full/10....
@nejm.org
#CardioSky #MedSky #Cardiology #AtrialFibrillation
January 24, 2025 at 2:25 PM
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.
www.nejm.org/doi/full/10....
@nejm.org
#CardioSky #MedSky #Cardiology #AtrialFibrillation
www.nejm.org/doi/full/10....
@nejm.org
#CardioSky #MedSky #Cardiology #AtrialFibrillation
The circular economy:
"Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed the drug abelacimab from Novartis in 2019, providing $250mn for clinical trials involving patients at high risk of cardiovascular problems."
www.ft.com/content/6d24...
"Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed the drug abelacimab from Novartis in 2019, providing $250mn for clinical trials involving patients at high risk of cardiovascular problems."
www.ft.com/content/6d24...
Novartis agrees $3bn deal to buy heart drug biotech from Blackstone
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019
www.ft.com
February 12, 2025 at 3:18 PM
The circular economy:
"Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed the drug abelacimab from Novartis in 2019, providing $250mn for clinical trials involving patients at high risk of cardiovascular problems."
www.ft.com/content/6d24...
"Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed the drug abelacimab from Novartis in 2019, providing $250mn for clinical trials involving patients at high risk of cardiovascular problems."
www.ft.com/content/6d24...
Looks like there’s a new kid on the block…
Abelacimab (MAB targeting FXI)
Fewer bleeding events (Primary EP)
But also higher embolic stroke events.
#emimcc
www.nejm.org/doi/full/10....
Abelacimab (MAB targeting FXI)
Fewer bleeding events (Primary EP)
But also higher embolic stroke events.
#emimcc
www.nejm.org/doi/full/10....
January 23, 2025 at 12:15 AM
Looks like there’s a new kid on the block…
Abelacimab (MAB targeting FXI)
Fewer bleeding events (Primary EP)
But also higher embolic stroke events.
#emimcc
www.nejm.org/doi/full/10....
Abelacimab (MAB targeting FXI)
Fewer bleeding events (Primary EP)
But also higher embolic stroke events.
#emimcc
www.nejm.org/doi/full/10....
17/What other clinical trials for FXI/XIa inhibitors are in progress?
January 14, 2026 at 8:10 PM
17/What other clinical trials for FXI/XIa inhibitors are in progress?
Among older patients with #AtrialFibrillation, abelacimab reduced major or clinically relevant bleeding vs rivaroxaban, with a greater absolute risk reduction in those aged ≥75 years. ja.ma/3ZZ0T0i
March 23, 2026 at 12:00 PM
Among older patients with #AtrialFibrillation, abelacimab reduced major or clinically relevant bleeding vs rivaroxaban, with a greater absolute risk reduction in those aged ≥75 years. ja.ma/3ZZ0T0i
“Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation."
Publié ce jour dans le @nejm.org.
#Medsky #Cardiology
www.nejm.org/doi/full/10....
Publié ce jour dans le @nejm.org.
#Medsky #Cardiology
www.nejm.org/doi/full/10....
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation | NEJM
Abelacimab is a fully human monoclonal antibody that binds to the inactive form of
factor XI and blocks its activation. The safety of abelacimab as compared with a direct
oral anticoagulant in pati...
www.nejm.org
January 23, 2025 at 12:30 PM
“Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation."
Publié ce jour dans le @nejm.org.
#Medsky #Cardiology
www.nejm.org/doi/full/10....
Publié ce jour dans le @nejm.org.
#Medsky #Cardiology
www.nejm.org/doi/full/10....
Abelacimab Shows Significant Reduction in Bleeding Events for Atrial Fibrillation Patients
www.thailandmedical.news/news/abelaci...
www.thailandmedical.news/news/abelaci...
Abelacimab Shows Significant Reduction in Bleeding Events for Atrial Fibrillation Patients - Thailand Medical News
www.thailandmedical.news
January 30, 2025 at 7:47 AM
Abelacimab Shows Significant Reduction in Bleeding Events for Atrial Fibrillation Patients
www.thailandmedical.news/news/abelaci...
www.thailandmedical.news/news/abelaci...
We authored the editorial “Science Behind the Study” for
@NEJM, focusing on the AZALEA-TIMI 71 trial, a phase 2b study of the Factor XI inhibitor abelacimab in patients with atrial fibrillation.
@NEJM, focusing on the AZALEA-TIMI 71 trial, a phase 2b study of the Factor XI inhibitor abelacimab in patients with atrial fibrillation.
January 23, 2025 at 5:37 AM
We authored the editorial “Science Behind the Study” for
@NEJM, focusing on the AZALEA-TIMI 71 trial, a phase 2b study of the Factor XI inhibitor abelacimab in patients with atrial fibrillation.
@NEJM, focusing on the AZALEA-TIMI 71 trial, a phase 2b study of the Factor XI inhibitor abelacimab in patients with atrial fibrillation.
Working link www.nejm.org/doi/full/10....
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation | NEJM
Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in pati...
www.nejm.org
January 23, 2025 at 7:01 PM
Working link www.nejm.org/doi/full/10....
Final AZALEA-TIMI 71 results confirm #AHA23 buzz: abelacimab ↓major/clinically relevant nonmajor bleeding compared w/rivaroxaban in patients w/AF and mod-to-high stroke risk. However, we must wait for Ph3 data to understand effects on stroke prevention. #Medsky #Cardiosky #Cardiology
In patients with atrial fibrillation and moderate-to-high risk of stroke, abelacimab, a monoclonal antibody that inhibits activation of factor XI, led to fewer bleeding events than rivaroxaban. Read the full AZALEA–TIMI 71 trial results: nej.md/3PJcknN
#MedSky #Cardiology
#MedSky #Cardiology
February 5, 2025 at 6:05 PM
Final AZALEA-TIMI 71 results confirm #AHA23 buzz: abelacimab ↓major/clinically relevant nonmajor bleeding compared w/rivaroxaban in patients w/AF and mod-to-high stroke risk. However, we must wait for Ph3 data to understand effects on stroke prevention. #Medsky #Cardiosky #Cardiology
Novartis unveils breakthrough data at #ESC2025, from Leqvio & Entresto to pipeline assets pelacarsen & abelacimab, driving a new era in #Cardiovascular innovation. 💙
#HeartHealth #Novartis #CVDInnovation #News #Interview
#HeartHealth #Novartis #CVDInnovation #News #Interview
Novartis sharpens focus on cardiovascular innovation at ESC 2025
Novartis exec, Dr Glaser, highlights Leqvio, pelacarsen, abelacimab, and Entresto in new data advancing cardiovascular care.
druganddeviceworld.com
September 1, 2025 at 4:09 PM
Novartis unveils breakthrough data at #ESC2025, from Leqvio & Entresto to pipeline assets pelacarsen & abelacimab, driving a new era in #Cardiovascular innovation. 💙
#HeartHealth #Novartis #CVDInnovation #News #Interview
#HeartHealth #Novartis #CVDInnovation #News #Interview
Novartis unveils breakthrough data at #ESC2025, from Leqvio & Entresto to pipeline assets pelacarsen & abelacimab, driving a new era in #Cardiovascular innovation. 💙
#HeartHealth #Novartis #CVDInnovation #News #Interview
#HeartHealth #Novartis #CVDInnovation #News #Interview
Novartis sharpens focus on cardiovascular innovation at ESC 2025
Novartis exec, Dr Glaser, highlights Leqvio, pelacarsen, abelacimab, and Entresto in new data advancing cardiovascular care.
druganddeviceworld.com
September 1, 2025 at 4:09 PM
Novartis unveils breakthrough data at #ESC2025, from Leqvio & Entresto to pipeline assets pelacarsen & abelacimab, driving a new era in #Cardiovascular innovation. 💙
#HeartHealth #Novartis #CVDInnovation #News #Interview
#HeartHealth #Novartis #CVDInnovation #News #Interview
New study: Abelacimab, a monoclonal antibody, reduced bleeding events by 62-69% vs. rivaroxaban in pts w/ a fib at mod-high stroke risk. Abelacimab lowered factor XI levels by 97-99% at 3 months. Adverse events were similar across groups. #MedEd #MedSky #CardioSky https://buff.ly/4jypphd
January 29, 2025 at 1:42 AM
New study: Abelacimab, a monoclonal antibody, reduced bleeding events by 62-69% vs. rivaroxaban in pts w/ a fib at mod-high stroke risk. Abelacimab lowered factor XI levels by 97-99% at 3 months. Adverse events were similar across groups. #MedEd #MedSky #CardioSky https://buff.ly/4jypphd